Skip to main content

Table 1 Baseline demographic and clinical characteristics of the blastocysts classified by ploidy status

From: The morphokinetic signature of human blastocysts with mosaicism and the clinical outcomes following transfer of embryos with low-level mosaicism

 

Euploid (N = 386)

Mosaic (N = 99)

Mosaic with aneuploid (N = 67)

Aneuploid (N = 371)

P value

PGT indication

    

4.10E-10

 Patients undergoing PGT-A (n = 486)

238 (61.66%)

68 (68.69%)

30 (44.78%)

150 (40.43%)

 

 Patients undergoing PGT-SR (n = 437)

148 (38.34%)

31 (31.31%)

37 (55.22%)

221 (59.57%)

 

Female age (year)

 Patients undergoing PGT-A

33.00 (30.00, 36.00)a

33.00 (30.25, 36.75)a

34.00 (30.00, 38.00)ab

36.00 (31.00, 39.00)b

1.07E-04

 Patients undergoing PGT-SR

30.00 (28.00, 32.00)

30.00 (27.00, 32.00)

30.00 (27.00, 32.00)

30.00 (27.50, 32.00)

0.977

Male age (year)

 Patients undergoing PGT-A

34.00 (31.00, 38.00)a

34.50 (31.25, 38.00)ab

35.50 (32.00, 39.50)ab

36.50 (32.75, 41.00)b

0.001

 Patients undergoing PGT-SR

31.00 (29.00, 34.00)

32.00 (29.00, 33.00)

31.00 (28.00, 34.50)

31.00 (29.00, 34.00)

0.847

BMI (kg/m2)

21.21 (19.53, 22.96)

21.48 (19.53, 22.94)

21.25 (19.71, 22.89)

22.03 (20.03, 23.31)

0.076

Basal estradiol (pg/ml)

40.50 (31.00, 55.00)ab

46.00 (33.00, 60.00)a

37.00 (29.00, 52.00)b

38.00 (30.00, 53.00)b

0.008

Basal progesterone (ng/ml)

0.50 (0.30, 0.80)

0.50 (0.40, 0.80)

0.55 (0.40, 0.80)

0.50 (0.30, 0.80)

0.964

Basal luteinizing hormone (mIU/ml)

4.50 (3.30, 6.40)

4.30 (3.40, 6.90)

4.30 (3.10, 5.40)

4.30 (3.40, 5.80)

0.260

Basal follicle-stimulating hormone (mIU/ml)

7.40 (6.20, 8.30)

7.40 (6.30, 8.10)

7.50 (6.30, 8.30)

7.30 (6.10, 8.30)

0.716

Antral follicle count

17.00 (13.00, 23.00)

16.00 (13.00, 24.00)

16.00 (13.00, 22.00)

19.00 (13.00, 23.00)

0.251

Ovarian stimulation protocol

    

0.303

 Short GnRH agonist protocol

213 (55.18%)

48 (48.48%)

36 (53.73%)

218 (58.76%)

 

 GnRH antagonist protocol

173 (44.82%)

51 (51.52%)

31 (46.27%)

153 (41.24%)

 

No. of controlled ovarian stimulation cycles

1.00 (1.00, 2.00)

1.00 (1.00, 2.00)

1.00 (1.00, 2.00)

1.00 (1.00, 2.00)

0.974

Gonadotropin dose (ampoules, 75 IU/ampoule)

26.50 (18.00, 33.00)a

24.00 (16.00, 32.00)a

30.00 (20.00, 40.00)ab

29.00 (19.00, 40.00)b

0.001

During of stimulation days

10.00 (9.00, 11.00)ab

9.00 (8.00, 10.00)a

10.00 (9.00, 12.00)b

10.00 (9.00, 11.00)b

0.002

  1. Data are presented as Median (interquartile range) for continuous variable or Number (%) for categorical variable
  2. P values are calculated using Kruskal–Wallis tests and Bonferroni post hoc for continuous variable and χ2 tests for categorical variable
  3. Bolded P values reached statistical significance
  4. Median with common superscripts across columns are not significantly different
  5. PGT-A preimplantation genetic testing for aneuploidy, PGT-SR preimplantation genetic testing for structural rearrangements
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us